Labcorp has launched the Neurofilament Light Chain (NfL) blood test to identify and verify signs of neuronal damage related to various neurodegenerative diseases and neuronal injury.
The biomarker test measures NfL levels through standard blood collection. A rise in NfL levels can signal neuronal injury associated with either concussions or neurodegenerative diseases.
“NfL is a simple, objective blood test that provides direct evidence of neuronal damage,” said Brian Caveney, MD, chief medical officer and President, Labcorp Diagnostics. “In making this test widely available, Labcorp is supporting neurologists with a tool they’ve been asking for that enables faster diagnoses, better treatment decisions and improved patient care.”
Several factors can influence NfL levels, including exercise, blood volume, and body mass index. Additionally, NfL levels measured in the morning have been found to more than 10% higher than those measured in the evening. Serum NfL levels may also be decreased in patients with high immunoglobulin G levels.
The NfL test is available to order at www.labcorp.com/nfl.
- Labcorp launches new test to identify and confirm neurodegenerative disease. News release. Labcorp. Accessed July 13, 2022. https://www.businesswire.com/news/home/20220713005453/en/Labcorp-Launches-New-Test-to-Identify-and-Confirm-Neurodegenerative-Disease
- Neurofilament Light Chain, Serum. Labcorp. Accessed July 13, 2022. https://www.labcorp.com/tests/140455/neurofilament-light-chain-serum
This article originally appeared on MPR